Home Family Medicine A Safe Diagnostic Model

A Safe Diagnostic Model

📋 Key Information Summary

📋
  • Probability diagnosis first: Always consider what is statistically most likely based on prevalence in the presenting demographic before exploring rarer diagnoses.
  • Serious not-to-be-missed diagnoses: Every presentation must be screened against potentially life-threatening conditions that could be hiding behind common symptoms.
  • The seven masquerades: Depression, diabetes mellitus, drugs (medication adverse effects), anaemia, thyroid dysfunction, urinary tract infection, and spinal dysfunction can mimic many other conditions and must be excluded in undifferentiated illness.
  • Diagnostic triads: Classic symptom clusters (e.g., the triad of headache, vomiting, and papilloedema for raised intracranial pressure) provide rapid pattern recognition for serious diagnoses.
  • Red flags are non-negotiable: Unintentional weight loss, unexplained fever, night sweats, persistent lymphadenopathy, and new neurological deficits demand urgent investigation regardless of the probability diagnosis.
  • Use a two-step approach: Step 1 — form a working probability diagnosis. Step 2 — actively ask "What serious or treatable condition might I miss?"
  • Masquerades are common in Australian general practice: Depression and diabetes are among the top reasons for GP encounters (BEACH data); always consider them in chronic, vague, or multisystem complaints.
  • Drugs as a cause of illness: Polypharmacy in elderly Australians makes iatrogenic disease a leading masquerade — always review the medication list.
  • Aboriginal and Torres Strait Islander populations: Higher prevalence of diabetes, renal disease, rheumatic heart disease, and later presentation means the "probability diagnosis" shifts and masquerades are even more important to exclude.
  • Safety-netting is part of the model: If the diagnosis is uncertain, document a safety-net plan with time-based review, specific return criteria, and clear communication to the patient.
  • The model applies to every presentation: Whether a patient presents with headache, fatigue, chest pain, or abdominal discomfort, the four-step diagnostic framework provides a structured, reproducible approach to safe diagnosis.

Introduction & Australian Context

General practice in Australia is characterised by undifferentiated presentations in a time-constrained environment. The average GP consultation is approximately 15–18 minutes, and patients frequently present with symptoms rather than confirmed diagnoses. A systematic diagnostic framework is therefore essential to ensure patient safety and diagnostic accuracy.

The Safe Diagnostic Model, widely attributed to Professor John Murtagh and embedded in Australian GP training curricula, provides a four-component framework that can be applied to virtually any presenting complaint:

  1. The probability diagnosis — What is most likely?
  2. Serious "not to be missed" conditions — What dangerous diagnosis could this be?
  3. The seven primary masquerades — What conditions commonly mimic other diseases?
  4. Diagnostic triads and red flags — What symptom clusters or alarm features point to specific diagnoses?

According to the Bettering the Evaluation and Care of Health (BEACH) programme, the most common reasons for GP encounters in Australia include hypertension, depression, upper respiratory tract infections, diabetes, and musculoskeletal complaints. Many of these overlap with the seven masquerades, reinforcing the importance of a structured diagnostic approach.

This model is mandated in the Royal Australian College of General Practitioners (RACGP) curriculum as a foundational competency. It is designed to reduce diagnostic error — which accounts for an estimated 5–15% of diagnostic decisions in primary care — by forcing deliberate, structured thinking at every consultation.

⚠️
Cognitive bias alert: Anchoring on the probability diagnosis without actively considering the masquerades and serious alternatives is the most common cause of diagnostic error in general practice. Always complete all four components of the model before finalising a management plan.

The Probability Diagnosis

The probability diagnosis is the condition that is statistically most likely given the patient's age, sex, demographic background, and presenting symptom(s). It forms the starting point — but never the endpoint — of the diagnostic process.

Principles of Probabilistic Reasoning

  • Base rate matters: Common conditions are common. A 45-year-old woman presenting with fatigue is more likely to have iron deficiency or depression than Addison's disease.
  • Age and sex modify probability: Chest pain in a 20-year-old is most likely musculoskeletal; in a 65-year-old male smoker, acute coronary syndrome must be considered first.
  • Prevalence in the local population: In an area with high rates of type 2 diabetes and obesity (e.g., outer metropolitan or rural Australia), metabolic causes of fatigue are more probable than in low-prevalence populations.
  • Time course matters: Acute onset favours infection, vascular events, and trauma; chronic symptoms favour degenerative, autoimmune, or neoplastic processes.

Common Probability Diagnoses by Presenting Complaint

Presenting Complaint Most Likely Diagnosis Key Demographic
Headache Tension-type headache All ages, especially 20–50 years
Chest pain Musculoskeletal / GORD Young adults; ACS if >40 years + risk factors
Fatigue Depression / anaemia / viral illness All ages
Abdominal pain Irritable bowel syndrome / functional dyspepsia Young to middle-aged adults
Low back pain Mechanical / non-specific LBP Adults 20–60 years
Cough Upper respiratory tract infection Children and adults; consider asthma if recurrent
Dizziness Benign paroxysmal positional vertigo Older adults (>50 years)
Sore throat Viral pharyngitis All ages; GABS if fever + no cough in children
💡
Clinical pearl: The probability diagnosis is your starting hypothesis. It is perfectly acceptable to treat the probability diagnosis while simultaneously investigating for serious alternatives — this is the hallmark of safe general practice.

Serious "Not to be Missed" Conditions

For every presenting complaint, the clinician must ask: "What serious or life-threatening condition could this patient have?" This is the safety-critical step in the diagnostic model. Missing these diagnoses can result in significant morbidity or mortality, and in medicolegal terms, failure to consider them constitutes a breach of duty of care.

High-Risk Diagnoses by Presenting Complaint

Presenting Complaint Serious "Not to be Missed" Diagnoses
Headache Subarachnoid haemorrhage, meningitis, giant cell arteritis, space-occupying lesion, acute glaucoma, carbon monoxide poisoning
Chest pain Acute coronary syndrome, pulmonary embolism, aortic dissection, tension pneumothorax, oesophageal rupture
Abdominal pain Ruptured AAA, ectopic pregnancy, bowel obstruction, mesenteric ischaemia, pancreatitis, perforated viscus
Fatigue Malignancy, heart failure, Addisonian crisis, severe anaemia, chronic infection (endocarditis, TB)
Weight loss Occult malignancy, hyperthyroidism, diabetes mellitus, chronic infection, coeliac disease
Dizziness Posterior circulation stroke, cardiac arrhythmia, aortic stenosis, severe anaemia
Back pain Cauda equina syndrome, spinal cord compression, aortic aneurysm, vertebral osteomyelitis, malignancy
Cough Lung cancer, pulmonary embolism, tuberculosis, whooping cough (pertussis) in infants
🚨
Do not anchor: The most dangerous cognitive error is diagnosing the probability condition and failing to actively exclude the serious alternative. A patient with "tension headache" who has a thunderclap onset, new neurological signs, or age >50 with new headache must be investigated for subarachnoid haemorrhage or space-occupying lesion before reassurance is given.

When to Escalate Immediately

  • Haemodynamic instability (tachycardia, hypotension, diaphoresis)
  • Altered conscious state or new focal neurological deficit
  • Severe, sudden-onset pain ("worst ever" or thunderclap)
  • Respiratory distress
  • Signs of peritonism or acute abdomen
  • Suspected anaphylaxis or sepsis
  • Active suicidal ideation with plan and intent

If any of the above features are present, arrange immediate transfer to the emergency department via ambulance (000) and initiate resuscitation as indicated. Do not delay for investigations that are available at the hospital.

The Seven Primary Masquerades

The seven masquerades are conditions that are common, often insidious in onset, and capable of producing a wide variety of symptoms that mimic many other diseases. They must be actively considered in any patient with vague, chronic, or multisystem complaints. Failure to exclude them is a major source of diagnostic error in Australian general practice.

⚠️
Murtagh's Rule of the Masquerades: If a patient presents with symptoms that do not fit a clear diagnostic pattern, or if a seemingly straightforward diagnosis is not responding to appropriate treatment, always consider whether one of the seven masquerades is the underlying cause.

1. Depression

Depression is the most common masquerade in Australian general practice and is frequently under-diagnosed. It may present as fatigue, insomnia, chronic pain, headache, gastrointestinal disturbance, weight change, poor concentration, or somatic complaints with no organic cause. Approximately 1 million Australians experience depression in any given year (ABS National Survey of Mental Health and Wellbeing), yet many do not present with mood disturbance as their primary complaint.

  • Screen with PHQ-2 or PHQ-9 in patients with unexplained physical symptoms
  • Ask directly about low mood, anhedonia, hopelessness, and suicidal ideation
  • Consider in all patients with chronic fatigue, chronic pain, or medically unexplained symptoms
  • First-line treatment: SSRIs (sertraline, escitalopram) + psychological therapy (CBT)

2. Diabetes Mellitus

Type 2 diabetes affects approximately 1.3 million Australians (AIHW 2023) and may remain undiagnosed for years. It can present with fatigue, recurrent infections (especially candidiasis and urinary tract infections), impaired wound healing, blurred vision, peripheral neuropathy, or as an incidental finding on routine blood tests. Type 1 diabetes, while less common, can present acutely at any age.

  • Screen with fasting glucose and HbA1c in any patient with risk factors (age ≥45, BMI ≥30, family history, PCOS, gestational diabetes history, Aboriginal or Torres Strait Islander background)
  • Consider in all patients with recurrent infections, non-healing wounds, or unexplained polyuria/polydipsia
  • Diagnosis: HbA1c ≥6.5% (48 mmol/mol), fasting glucose ≥7.0 mmol/L, or 2-hour OGTT ≥11.1 mmol/L
  • First-line treatment: metformin + lifestyle modification

3. Drugs (Medication Adverse Effects)

Iatrogenic disease is a leading cause of morbidity, particularly in elderly Australians taking multiple medications. The average Australian aged ≥65 takes 5 or more regular medications. Drugs can cause or contribute to fatigue, dizziness, falls, confusion, constipation, urinary incontinence, depression, cough (ACE inhibitors), electrolyte disturbance, hypotension, and sexual dysfunction.

  • Always review the complete medication list — including over-the-counter, herbal, and complementary products
  • Use the Beers Criteria or STOPP/START criteria to identify potentially inappropriate prescribing
  • Common offenders: benzodiazepines, opioids, anticholinergics, NSAIDs, corticosteroids, antihypertensives, psychotropic agents
  • Consider a Home Medicines Review (MBS Item 900) for patients on ≥5 medications or experiencing adverse effects

4. Anaemia

Anaemia affects approximately 5% of Australian men and 10% of women, with higher rates in Aboriginal and Torres Strait Islander communities, pregnant women, and the elderly. It is a sign, not a diagnosis — the underlying cause must always be sought. Anaemia may present as fatigue, dyspnoea on exertion, pallor, tachycardia, dizziness, or angina in the elderly.

  • Iron deficiency anaemia is the most common cause in premenopausal women and young children; consider coeliac disease, menorrhagia, and GI blood loss
  • In men and postmenopausal women, iron deficiency must be investigated for GI malignancy (colonoscopy + upper GI endoscopy) until proven otherwise
  • Macrocytic anaemia: check B12, folate; consider alcohol, liver disease, hypothyroidism, myelodysplasia
  • Microcytic anaemia: iron studies, haemoglobin electrophoresis (thalassaemia trait common in SE Asian and Mediterranean populations)

5. Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism can present with a wide range of nonspecific symptoms. Hypothyroidism may mimic depression, fatigue, weight gain, constipation, cold intolerance, and cognitive impairment. Hyperthyroidism may present as anxiety, palpitations, weight loss, tremor, heat intolerance, or atrial fibrillation. Subclinical thyroid disease is particularly common in older Australians.

  • Screen with TSH as the first-line investigation; follow up with free T4 and free T3 if abnormal
  • Consider thyroid dysfunction in all patients with unexplained fatigue, weight change, mood disturbance, or new atrial fibrillation
  • Autoimmune thyroid disease (Hashimoto's and Graves') is more common in women and those with other autoimmune conditions (coeliac disease, type 1 diabetes)
  • Hypothyroidism: levothyroxine (Eutroxsig®, Oroxine®); Hyperthyroidism: carbimazole or propylthiouracil, radioactive iodine, or surgery

6. Urinary Tract Infection (Occult)

Urinary tract infections may present with typical symptoms (dysuria, frequency, urgency) but can also masquerade as fatigue, confusion (especially in the elderly), unexplained fever, loss of appetite, or general malaise. Recurrent UTIs in women are extremely common, and occult UTIs in elderly or cognitively impaired patients are frequently missed.

  • Consider UTI in any elderly patient presenting with confusion, falls, or unexplained deterioration
  • Always obtain a midstream urine (MSU) for culture before initiating antibiotics where possible
  • Asymptomatic bacteriuria is common in elderly women and catheterised patients — do not treat unless pregnant or prior to urological procedures
  • First-line empiric treatment: trimethoprim 300 mg PO nocte for 3 days (uncomplicated female UTI); nitrofurantoin 100 mg PO BD for 5 days as alternative

7. Spinal Dysfunction

Cervical and lumbar spinal dysfunction (including degenerative disc disease, facet joint arthropathy, and nerve root compression) can produce referred pain that mimics cardiac disease, abdominal pathology, pulmonary disease, or peripheral vascular disease. Thoracic spine dysfunction may simulate chest pain of cardiac origin, and lumbar dysfunction may produce symptoms resembling hip pathology or vascular claudication.

  • Cervical spine: Can refer pain to the head, shoulder, arm, and chest; may cause headache and vertigo
  • Thoracic spine: Can mimic angina, pleurisy, or abdominal pain
  • Lumbar spine: Can mimic sciatica, hip pathology, peripheral vascular disease, or abdominal pain
  • Diagnosis: careful history (pain with movement/posture), physical examination (range of motion, provocative tests), and imaging only when red flags present

Summary of the Seven Masquerades

Masquerade Common Mimicked Conditions Key Screening Test
Depression Chronic fatigue, chronic pain, IBS, headache PHQ-9
Diabetes mellitus Recurrent infections, neuropathy, fatigue, visual changes HbA1c, fasting glucose
Drugs Fatigue, confusion, dizziness, falls, depression, GI symptoms Full medication review
Anaemia Fatigue, dyspnoea, angina, cognitive impairment FBC, iron studies
Thyroid dysfunction Depression, anxiety, AF, weight change, constipation TSH
Urinary tract infection Confusion (elderly), unexplained fever, malaise Urinalysis + MSU culture
Spinal dysfunction Chest pain, abdominal pain, headache, limb pain Physical examination + provocative tests
Practical tip: A simple "masquerade screen" — FBC, EUC, LFT, TSH, glucose/HbA1c, iron studies, urinalysis, and a medication review — can be performed in a single pathology request and will exclude four of the seven masquerades within 24 hours.

Diagnostic Triads & Red Flags

Diagnostic triads are classic clusters of three symptoms, signs, or investigations that together strongly suggest a specific diagnosis. They serve as rapid pattern-recognition tools that can be applied at the bedside or in the consultation room. Red flags are individual features that, regardless of the overall clinical picture, mandate urgent investigation or referral.

Key Diagnostic Triads

Triad Component 1 Component 2 Component 3 Suggested Diagnosis
Raised ICP Headache Vomiting Papilloedema Space-occupying lesion / hydrocephalus
Cushing's triad Hypertension Bradycardia Irregular respirations Raised ICP / brainstem herniation
Charcot's triad Jaundice Right upper quadrant pain Fever / rigors Ascending cholangitis
Virchow's triad Venous stasis Endothelial injury Hypercoagulability Deep vein thrombosis / PE
Beck's triad Hypotension Muffled heart sounds Jugular venous distension Cardiac tamponade
Whipple's triad Symptoms of hypoglycaemia Low plasma glucose Relief with glucose administration Hypoglycaemia
Classic DKA Hyperglycaemia Ketonaemia / ketonuria Metabolic acidosis Diabetic ketoacidosis
Parkinson's triad Tremor (resting) Rigidity Bradykinesia Parkinson's disease
Diabetes insipidus Polyuria Polydipsia Dilute urine (low osmolality) Diabetes insipidus
Delirium Acute onset / fluctuating course Inattention Altered level of consciousness Delirium (screen for infection, drugs, metabolic causes)

Red Flags by System

Headache Red Flags
"SNOOP" Mnemonic
Systemic symptoms (fever, weight loss) · Neurological signs · Onset sudden (thunderclap) · Older age (>50, new onset) · Pattern change (progressive, worse in morning)
Action: Urgent CT brain ± LP; same-day referral
Back Pain Red Flags
"TUNA FISH" Mnemonic
Trauma · Unexplained weight loss · Neurological deficit · Age <20 or >55 · Fever · IV drug use · Steroid use · History of malignancy
Action: Urgent MRI spine ± emergent referral for cauda equina
Abdominal Pain Red Flags
Alarm Features
Peritonism · Rigidity · Unintentional weight loss · GI blood loss · Dysphagia · Persistent vomiting · New onset age >50 · Mass on palpation
Action: Urgent surgical/medical assessment; CT abdomen if unstable
Weight Loss Red Flags
Unexplained >5% in 6 months
Age >50 · Smoker · Alcohol excess · Night sweats · Lymphadenopathy · Change in bowel habit · Persistent cough · Dysphagia
Action: FBC, EUC, LFT, CRP, CXR, CT; 2-week wait referral

Applying the Model: A Worked Example

📝
Case: A 52-year-old woman presents with 3 months of fatigue, difficulty concentrating, and 4 kg weight loss.

Step 1 — Probability diagnosis: Depression (most common cause of fatigue and cognitive complaints in this age group).

Step 2 — Serious not to be missed: Occult malignancy (especially colorectal — new weight loss in >50), thyroid dysfunction, diabetes mellitus, chronic infection.

Step 3 — Masquerades: Depression (fits), diabetes (screen with HbA1c), thyroid disease (TSH), anaemia (FBC, iron studies), drugs (review medication list).

Step 4 — Triads and red flags: Weight loss in a >50-year-old is a red flag — requires baseline investigations including FBC, EUC, LFT, TSH, HbA1c, iron studies, CRP, coeliac serology, and age-appropriate cancer screening (bowel screening test, mammography). If no cause found, proceed to CT chest/abdomen/pelvis.

Safety-Netting & Diagnostic Follow-Up

Safety-netting is the final — and arguably most important — component of safe diagnostic practice. When a definitive diagnosis cannot be made at the initial consultation, the clinician must put in place a structured plan for follow-up.

The Safety-Net Framework

1
Time-Based Review
Schedule a specific follow-up appointment (not "come back if worse"). For most undifferentiated presentations, 1–2 weeks is appropriate. For suspected self-limiting illness, 5–7 days.
2
Explicit Return Criteria
Tell the patient exactly what worsening symptoms to watch for: "Come back immediately or go to the Emergency Department if you develop fever, vomiting, severe pain, confusion, or any new symptoms you're worried about."
3
Investigations Pending
Ensure all ordered investigations are followed up. Use a recall system — never assume normal results will reach the patient. Document a follow-up date for every outstanding result.
4
Document Your Reasoning
Record the differential diagnoses considered, the serious diagnoses excluded, and the plan. This protects both the patient and the clinician medicolegally.
🚨
Critical: Safety-netting is not a substitute for thorough initial assessment. "Come back if it gets worse" alone — without a time-based review, explicit criteria, and pending investigation follow-up — is inadequate safety-netting and exposes the clinician to significant medicolegal risk.

Special Populations

👶

Paediatric Considerations

Children often present atypically — the probability diagnosis shifts to include otitis media, viral URTI, and behavioural conditions.
Serious not to be missed: meningitis, intussusception, Wilms' tumour, leukaemia, non-accidental injury.
Masquerades in children: consider ADHD and learning difficulties masquerading as "behavioural problems," coeliac disease causing failure to thrive, and UTI presenting as unexplained fever.
Non-accidental injury: Always consider in children with inconsistent history, delay in presentation, or injuries inconsistent with the reported mechanism. Mandatory reporting obligations apply.
👴

Elderly Patients

Multiple comorbidities and polypharmacy make the "Drugs" masquerade especially important. Always conduct a medication review.
Atypical presentations are the rule, not the exception: myocardial infarction may present as confusion; UTI as falls; pneumonia as anorexia.
Delirium is a red flag in itself — always search for the precipitant (infection, medication, metabolic, pain, constipation, urinary retention).
Age-appropriate cancer screening should be reviewed; new symptoms in patients >55 warrant a lower threshold for investigation.
🫘

Renal Impairment

Chronic kidney disease is common in Australia (affecting ~10% of adults) and alters the probability diagnosis for many symptoms (fatigue, oedema, nausea).
Renal impairment affects drug dosing — always adjust medications renally (particularly antibiotics, metformin, lithium, NSAIDs).
Anaemia of CKD (erythropoietin deficiency) must be distinguished from iron deficiency — request iron studies and reticulocyte count.
🫁

Hepatic Impairment

Chronic liver disease (often alcohol-related or due to NAFLD) may present with fatigue, confusion (hepatic encephalopathy), coagulopathy, or oedema — all of which can mimic other conditions.
Drug metabolism is impaired — avoid or dose-adjust hepatically cleared medications (paracetamol max 2 g/day in severe liver disease, avoid NSAIDs, adjust benzodiazepines).
Hepatitis B and C screening should be considered in at-risk populations, particularly Aboriginal and Torres Strait Islander peoples and those born overseas in endemic regions.
🛡️

Immunocompromised Patients

In patients on immunosuppressive therapy, corticosteroids, or with HIV/AIDS, the probability diagnosis shifts — common infections may behave atypically, and opportunistic infections must be considered.
Fever in an immunocompromised patient is a medical emergency until proven otherwise — investigate broadly (FBC, blood cultures, CRP, CXR) and consider empirical antibiotics.
Serious not to be missed: Pneumocystis jirovecii pneumonia, CMV reactivation, invasive fungal infections, disseminated TB.
🤰 Pregnancy
Pregnancy modifies the probability diagnosis for many symptoms: nausea (hyperemesis gravidarum vs. molar pregnancy), breathlessness (normal physiological vs. PE), headache (pre-eclampsia vs. migraine).
Serious not to be missed: ectopic pregnancy, pre-eclampsia/eclampsia, HELLP syndrome, pulmonary embolism, acute fatty liver of pregnancy.
Many investigations and treatments are modified in pregnancy — always check pregnancy safety before ordering imaging or prescribing medications (use ADEC/TGA pregnancy categories).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

The Safe Diagnostic Model is particularly critical in Aboriginal and Torres Strait Islander health. Due to higher prevalence of chronic disease, later presentation, and the ongoing effects of systemic inequity, the probability diagnosis shifts for many common presentations, and the masquerades become even more important to exclude.

Modified Probability Considerations

  • Type 2 diabetes is 3–4 times more common in Aboriginal and Torres Strait Islander peoples than non-Indigenous Australians (AIHW 2023). It should be considered early in any presentation involving fatigue, recurrent infection, or unexplained weight change.
  • Chronic kidney disease prevalence is approximately 2.5 times higher, and progression to end-stage kidney disease is faster — screen proactively with eGFR and albumin-to-creatinine ratio (ACR).
  • Rheumatic heart disease (RHD) remains a significant cause of cardiac morbidity in remote communities. A new cardiac murmur or symptoms of heart failure in a young Aboriginal or Torres Strait Islander person must prompt consideration of RHD, not just rheumatic or degenerative valve disease.
  • Acute rheumatic fever (ARF) is rare in the non-Indigenous population but remains a diagnosis of concern in children and young adults in northern and central Australia. The revised Jones criteria (2015) include low-risk and high-risk population thresholds.
  • Hepatitis B is endemic in many Aboriginal and Torres Strait Islander communities — universal screening is recommended for those not previously tested.
  • Trachoma remains endemic in remote Aboriginal communities in central and northern Australia — consider in any child with recurrent conjunctivitis or an adult with trichiasis.

Barriers to Diagnosis

Remote access
Many Aboriginal and Torres Strait Islander Australians live in remote or very remote areas where specialist and diagnostic imaging access is limited. Point-of-care testing (e.g., iSTAT for troponin, HbA1c, eGFR) and telehealth consultations are essential for timely diagnosis.
Cultural safety
Effective diagnosis requires culturally safe communication. Many patients may not feel comfortable disclosing symptoms related to mental health, sexual health, or substance use to a non-Indigenous clinician. Aboriginal and Torres Strait Islander health workers and liaison officers play a critical role in facilitating disclosure and trust.
Communication
English may be a second or third language for some patients in remote communities. Use plain language, visual aids, and interpreters where available. Allow extra consultation time for culturally appropriate engagement.
Health literacy
Diagnostic explanations should be adapted to the patient's health literacy level. Use teach-back methods to confirm understanding of investigations, follow-up plans, and safety-netting instructions.
Systemic racism and mistrust
Historical and ongoing experiences of racism in healthcare contribute to delayed presentation and disengagement. Building long-term therapeutic relationships through continuity of care is essential for safe diagnosis. Acknowledge the social determinants of health — housing, education, employment, food security — that influence disease prevalence and presentation.

Implications for the Diagnostic Model

  • Lower the threshold for screening for diabetes, CKD, RHD, hepatitis B, and rheumatic fever in Aboriginal and Torres Strait Islander patients.
  • Consider the seven masquerades actively — depression and diabetes are particularly prevalent but often under-diagnosed.
  • Use the MBS Indigenous Health Assessment (Item 715) as an opportunity for comprehensive masquerade screening.
  • Involve Aboriginal and Torres Strait Islander health workers in the diagnostic process wherever possible — they are an invaluable bridge between the patient and the clinical team.
💚
Closing the Gap: The Australian Government's National Agreement on Closing the Gap (2020) commits to culturally safe healthcare and equitable access to diagnostic services. The Safe Diagnostic Model, applied with cultural humility and appropriate resourcing, contributes directly to reducing diagnostic delay and improving health outcomes for Aboriginal and Torres Strait Islander peoples.

📚 References

  1. 1. Murtagh J. Murtagh's General Practice. 8th ed. North Ryde: McGraw-Hill Education; 2023.
  2. 2. Murtagh J. Murtagh's Patient Skills. 2nd ed. Sydney: McGraw-Hill; 2020.
  3. 3. Royal Australian College of General Practicians. RACGP Curriculum for Australian General Practice 2022: Priority Areas. Melbourne: RACGP; 2022.
  4. 4. Britt H, Miller GC, Henderson J, et al. General Practice Activity in Australia 2021–22. Sydney: Sydney University Press; 2022. (BEACH programme)
  5. 5. Australian Institute of Health and Welfare. Diabetes in Australia. Cat. no. CVD 77. Canberra: AIHW; 2023.
  6. 6. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework: Summary Report. Canberra: AIHW; 2023.
  7. 7. Ely JW, Graber ML, Croskerry P. Checklists to reduce diagnostic errors. Acad Med. 2011;86(3):307–313.
  8. 8. Singh H, Meyer AN, Thomas EJ. The frequency of diagnostic errors in outpatient care: estimations from three large observational studies involving US adult populations. BMJ Qual Saf. 2014;23(9):727–731.
  9. 9. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  10. 10. O'Gorman C, Sherriff J, Khoo S-K, et al. Prevalence of type 2 diabetes mellitus in Aboriginal and Torres Strait Islander peoples: a systematic review. Aust N Z J Public Health. 2020;44(5):380–386.
  11. 11. Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia. Melbourne: Heart Foundation; 2018 (updated 2023).
  12. 12. Royal Australian College of General Practicians. Management of Type 2 Diabetes: A Handbook for General Practice. Melbourne: RACGP; 2020 (updated 2023).
  13. 13. Australian Bureau of Statistics. National Study of Mental Health and Wellbeing. ABS cat. no. 4327.0. Canberra: ABS; 2022.
  14. 14. Rheumatic Heart Disease Australia. RHD Aboriginal and Torres Strait Islander Guidelines: The Diagnosis of Acute Rheumatic Fever. Casuarina: RHDAustralia; 2020.
  15. 15. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–1292.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).